https://scholars.lib.ntu.edu.tw/handle/123456789/514113
DC 欄位 | 值 | 語言 |
---|---|---|
dc.contributor.author | HSIU-HAO CHANG | en_US |
dc.contributor.author | MENG-YAO LU | en_US |
dc.contributor.author | STEVEN SHINN-FORNG PENG | en_US |
dc.contributor.author | YUNG-LI YANG | en_US |
dc.contributor.author | Lin D.-T. | en_US |
dc.contributor.author | SHIANN-TANG JOU | en_US |
dc.contributor.author | Lin K.-H. | en_US |
dc.date.accessioned | 2020-09-22T08:51:43Z | - |
dc.date.available | 2020-09-22T08:51:43Z | - |
dc.date.issued | 2015 | - |
dc.identifier.issn | 0939-5555 | - |
dc.identifier.uri | https://scholars.lib.ntu.edu.tw/handle/123456789/514113 | - |
dc.description.abstract | Deferasirox is a novel once-daily, oral iron chelator. The aim of this study was to evaluate the long-term efficacy and tolerability of deferasirox in Taiwanese patients with transfusion-dependent β-thalassemia who have been treated with deferasirox for 7?years. Taiwanese patients aged ?2?years with transfusion-dependent β-thalassemia whose serum ferritin levels were ?1000?ng/mL and had started deferasirox treatment since December 2005 at the National Taiwan University Hospital were enrolled. Sixty patients were recruited for analysis, and 11 (18.3?%) patients discontinued deferasirox during the study. In the 42 patients included in the efficacy analysis, the mean serum ferritin levels decreased significantly by 2566?ng/mL after 7?years of treatment (P < 0.001). Forty-one of these patients received a cardiac T2* evaluation after 3?years of deferasirox treatment, and the mean cardiac T2* value increased significantly from 30.6 ± 16.6 to 45.9 ± 22.6?ms after 7?years of deferasirox treatment (P < 0.001). Deferasirox-related adverse events assessed by investigators were reported in 46 (76.7?%) patients. The most common adverse events related to deferasirox were skin rashes (n = 29, 48.3?%), followed by abdominal pain (n = 23, 38.3?%) and diarrhea (n = 16, 26.7?%). Most adverse events were manageable. This study demonstrated that long-term treatment with deferasirox was effective in improving iron overload, including cardiac iron overload, in patients with transfusion-dependent β-thalassemia. Deferasirox was well tolerated; however, the incidences of common adverse events related to deferasirox appeared higher in our Taiwanese patients than other studies. ? 2015, The Author(s). | - |
dc.relation.ispartof | Annals of Hematology | - |
dc.subject.classification | [SDGs]SDG3 | - |
dc.subject.other | deferasirox; benzoic acid derivative; deferasirox; iron chelating agent; triazole derivative; abdominal pain; adolescent; adult; Article; beta thalassemia; child; diarrhea; drug efficacy; drug tolerability; drug withdrawal; Fanconi renotubular syndrome; female; ferritin blood level; human; hypertransaminasemia; iron chelation; iron overload; long term care; major clinical study; male; priority journal; rash; Taiwan; Taiwanese; transfusion; beta-Thalassemia; blood; blood transfusion; clinical trial; follow up; iron overload; preschool child; time factor; Adolescent; Adult; Benzoates; beta-Thalassemia; Blood Transfusion; Child; Child, Preschool; Female; Follow-Up Studies; Humans; Iron Chelating Agents; Iron Overload; Male; Taiwan; Time Factors; Triazoles | - |
dc.title | The long-term efficacy and tolerability of oral deferasirox for patients with transfusion-dependent β-thalassemia in Taiwan | en_US |
dc.type | journal article | en |
dc.identifier.doi | 10.1007/s00277-015-2476-y | - |
dc.identifier.pmid | 26404899 | - |
dc.identifier.scopus | 2-s2.0-84944075644 | - |
dc.relation.pages | 1945-1952 | - |
dc.relation.journalvolume | 94 | - |
dc.relation.journalissue | 12 | - |
item.fulltext | no fulltext | - |
item.grantfulltext | none | - |
item.openairetype | journal article | - |
item.openairecristype | http://purl.org/coar/resource_type/c_6501 | - |
item.cerifentitytype | Publications | - |
crisitem.author.dept | Pediatrics | - |
crisitem.author.dept | Pediatrics-NTUH | - |
crisitem.author.dept | Pediatrics-NTUH | - |
crisitem.author.dept | Pediatrics | - |
crisitem.author.dept | Radiology | - |
crisitem.author.dept | Medical Imaging-NTUH | - |
crisitem.author.dept | Nuclear Medicine-NTUH | - |
crisitem.author.dept | Pediatrics | - |
crisitem.author.dept | Laboratory Medicine | - |
crisitem.author.dept | Pediatrics-NTUH | - |
crisitem.author.dept | Laboratory Medicine-NTUH | - |
crisitem.author.dept | Pediatrics-NTUH | - |
crisitem.author.dept | Pediatrics | - |
crisitem.author.orcid | 0000-0003-1832-8509 | - |
crisitem.author.orcid | 0000-0003-4461-9967 | - |
crisitem.author.orcid | 0000-0002-8177-5187 | - |
crisitem.author.orcid | 0000-0002-3598-7218 | - |
crisitem.author.orcid | 0000-0003-1483-0403 | - |
crisitem.author.parentorg | College of Medicine | - |
crisitem.author.parentorg | National Taiwan University Hospital | - |
crisitem.author.parentorg | National Taiwan University Hospital | - |
crisitem.author.parentorg | College of Medicine | - |
crisitem.author.parentorg | College of Medicine | - |
crisitem.author.parentorg | National Taiwan University Hospital | - |
crisitem.author.parentorg | National Taiwan University Hospital | - |
crisitem.author.parentorg | College of Medicine | - |
crisitem.author.parentorg | College of Medicine | - |
crisitem.author.parentorg | National Taiwan University Hospital | - |
crisitem.author.parentorg | National Taiwan University Hospital | - |
crisitem.author.parentorg | National Taiwan University Hospital | - |
crisitem.author.parentorg | College of Medicine | - |
顯示於: | 醫學院附設醫院 (臺大醫院) |
在 IR 系統中的文件,除了特別指名其著作權條款之外,均受到著作權保護,並且保留所有的權利。